Sign inJoin waitlistJoin the waitlist

Joshua Zeidner

Chief of the Leukemia Research Program · University of North Carolina

Credentials: · · ·

History

Leukemia Research Program Division · University of North Carolina
Present

Research

Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy
Nature Biomedical Engineering · 2018 · 222 citations
Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy
JCI Insight · 2018 · 177 citations
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML
Blood · 2018 · 176 citations

MF
Matthew Foster
26 papers
Yazan Madanat
14 papers
CC
Catherine Coombs
13 papers · 11 as a fellow
IG
Ivana Gojo
13 papers
Tara Lin
13 papers
Alice Mims
12 papers
ES
Eytan Stein
12 papers
NM
Nathan Montgomery
12 papers
RS
Ronan Swords
12 papers
Amer Zeidan
11 papers
BS
Bruce Smith
10 papers
Daniel Richardson
10 papers

Clinical trials

Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML
Principal investigator · Not yet recruiting · Phase 2
UNC Lineberger Comprehensive Cancer Center
2026–2028
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
Principal investigator · Recruiting · Phase 2
Joshua Zeidner
2024–2031
Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2022–2027
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
Principal investigator · Recruiting · Phase 1
Meryx, Inc.
2022–2026